Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 655

Sort by

Sort Order Select

Journal Articles

MCL-1 and BCL-XL: blood brothers

Miriam Erlacher, Verena Labi

Blood (2021) 137 (14): 1850–1851.

https://doi.org/10.1182/blood.2020010569

Published: 2021

Journal Articles

Requirement for antiapoptotic MCL-1 during early erythropoiesis

Meghan E. Turnis, Ewa Kaminska, Kaitlyn H. Smith, Brittany J. Kartchner, Peter Vogel, Jonathan D. Laxton, Richard A. Ashmun, Paul A. Ney, Joseph T. Opferman

Blood (2021) 137 (14): 1945–1958.

https://doi.org/10.1182/blood.2020006916

Published: 2021

Includes: Supplemental data

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

Greta De Jong, Sophie E Levie, Remko Schotte, PhD, Wouter Pos, PhD, Daniel Go, Etsuko Yasuda, Madalina Cercel, Susan E van Hal-van Veen, Esmay Frankin, Anikó Szabó, MD, Julien Villaudy, PhD, Pauline M van Helden, PhD, Hans van Eenennaam, PhD, Hergen Spits, PhD, Anita W Rijneveld, MD PhD, Mette D Hazenberg, MD PhD

Blood (2019) 134 (Supplement_1): 4461.

https://doi.org/10.1182/blood-2019-127894

Published: 2019

Journal Articles

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

Jean-Baptiste Alberge, Sarthak Sinha, BSc, Ranjan Maity, PhD, Arzina Jaffer, Justin Donovan, Madison Kong, Stephane Minvielle, PhD, Paola Neri, MD PhD, Nizar Bahlis, MD

Blood (2019) 134 (Supplement_1): 686.

https://doi.org/10.1182/blood-2019-131981

Published: 2019

Journal Articles

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

Yun Dai, MD, Yue Sun, MS, Shaji K. Kumar, MD, Wei Wu, MD, Fengyan Jin, MD PhD

Blood (2019) 134 (Supplement_1): 687.

https://doi.org/10.1182/blood-2019-132051

Published: 2019

Journal Articles

MCL1 Inhibitors in Multiple Myeloma

Karin Vanderkerken, PhD, Kim De Veirman, Ken Maes, Eline Menu, PhD, Elke De Bruyne, PhD

Blood (2019) 134 (Supplement_1): SCI-12.

https://doi.org/10.1182/blood-2019-121104

Published: 2019

Journal Articles

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Jennifer Edelmann, MD PhD, Arran Dokal, MSc, PhD, Karlheinz Holzmann, Dr. rer. nat., David James Britton, BSc, PhD, Emma Vilventhraraja, MSc, PhD, Ryan Jack Smith, PhD, Mark S Cragg, Prof, Andrejs Braun, PhD, Hartmut Döhner, MD, Pedro Cutillas, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 1579.

https://doi.org/10.1182/blood-2019-128704

Published: 2019

Journal Articles

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Ayako Nogami, MD PhD BPharm, Daisuke Watanabe, MD, Keigo Okada, MD, PhD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Toshikage Nagao, MD, PhD, Shuji Tohda, MD, PhD, Osamu Miura, MD, PhD

Blood (2019) 134 (Supplement_1): 1425.

https://doi.org/10.1182/blood-2019-123183

Published: 2019

Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1369.

https://doi.org/10.1182/blood-2019-128618

Published: 2019

Journal Articles

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Alexandra Niedermayer, MSc, Stefanie Enzenmüller, PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Felix Seyfried, MD, Klaus-Michael Debatin, MD, Lüder Hinrich Meyer, MD

Blood (2019) 134 (Supplement_1): 3954.

https://doi.org/10.1182/blood-2019-126582

Published: 2019

Journal Articles

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Vrajesh Karkhanis, PhD, Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Abhishek Maiti, MBBS, Bernardo H Lara, James V Maher, Isean Bhalla, Nancy Shao, Michael R Green, PhD, Joseph D. Khoury, MD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 3961.

https://doi.org/10.1182/blood-2019-132041

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Lauren K. Meyer, Katherine Verbist, PhD, Sabrin Albeituni, PhD, Rachel Bassett, Michelle L. Hermiston, MD PhD, Kim E. Nichols, MD

Blood (2019) 134 (Supplement_1): 81.

https://doi.org/10.1182/blood-2019-129112

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

Jing Deng, PhD, Tingting Mao, MS, Xiaojing Huang, PhD, Li Rui, Guangfeng Wang, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD

Blood (2019) 134 (Supplement_1): 2573.

https://doi.org/10.1182/blood-2019-128708

Published: 2019

Journal Articles

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Mark Sellin, Ryan Mack, Matthew C. Rhodes, Lei Zhang, PhD, Wei Wei, Peter Breslin, PhD, Stephanie Berg, DO, Suming Huang, PhD, Richard Taylor, PhD, Jiwang Zhang, MD

Blood (2019) 134 (Supplement_1): 2666.

https://doi.org/10.1182/blood-2019-132030

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Raoul Tibes, MD PhD, Diego Ferreira Coutinho, PhD, Michael Tuen Tuen, Xufeng Chen, PhD, Christina Glytsou, Ioannis Aifantis, Sergey Shmelkov, MD

Blood (2019) 134 (Supplement_1): 2559.

https://doi.org/10.1182/blood-2019-130931

Published: 2019

Journal Articles

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Colin D. Godwin, MDMPhil, Olivia M. Bates, BA, Sae Rin Jean, PhD, George S. Laszlo, PhD, Eliotte E. Garling, BA, Mary E. Beddoe, BS, Michael H. Cardone, PhD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 2561.

https://doi.org/10.1182/blood-2019-126110

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

MCL-1 and BCL-XL: blood brothers

Requirement for antiapoptotic MCL-1 during early erythropoiesis

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

AT1412, a Patient-Derived Antibody in Development for the Treatment of CD9 Positive Precursor B-Acute Lymphoblastic Leukemia

IGLL5-BCL2L1 Rearrangement with Loss of BCL2 Dependency As Mechanism of Venetoclax Resistance in Multiple Myeloma (MM)

IRF4 Is Reciprocally Dysregulated Via NF-Κb-Dependent Expression and Loss-of-Function Mutations in Multiple Myeloma

MCL1 Inhibitors in Multiple Myeloma

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Characterization of Mechanisms of Acquired Venetoclax-Insensitivity in B-Cell Precursor Acute Lymphoblastic Leukemia

Efficacy of Targeted Therapy in Novel Pre-Clinical in Vitro and In Vivo Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

A Novel BCL-2/BCL-Xl Dual Inhibitor Overcomes Ibrutinib-Resistance Conferred By the Upregulation of Integrin Pathway and BCL-Xl

The Splicing Modulator GEX1A Exhibits Potent Anti-Leukemic Activity Both in Vitro and In Vivo through Inducing an MCL1 Splice-Switch in Pre-Clinical Models of Acute Myeloid Leukemia

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

DNA Damage Repair Interference By WEE1 Inhibition with AZD1775 Overcomes Combined Azacitidine and Venetoclax Resistance in Acute Myeloid Leukmeia (AML)

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only